These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 21971541)

  • 21. Bevacizumab and ovarian cancer.
    Lai GG; Penson RT
    Drugs Today (Barc); 2011 Sep; 47(9):669-81. PubMed ID: 21971541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
    Al Wadi K; Ghatage P
    Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.
    Teoh D; Secord AA
    Int J Gynecol Cancer; 2012 Mar; 22(3):348-59. PubMed ID: 22266932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.
    Monk BJ; Dalton H; Farley JH; Chase DM; Benjamin I
    Crit Rev Oncol Hematol; 2013 May; 86(2):161-75. PubMed ID: 23137764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab in the treatment of ovarian cancer.
    Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
    Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
    González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
    Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab in the treatment of ovarian cancer.
    Han ES; Monk BJ
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab in colorectal cancer: current and future directions.
    Yeung Y; Tebbutt NC
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1263-73. PubMed ID: 23113577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with bevacizumab in the management of epithelial ovarian cancer.
    Burger RA
    J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
    Han ES; Wakabayashi M; Leong L
    Curr Treat Options Oncol; 2013 Mar; 14(1):22-33. PubMed ID: 23288484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiogenesis as a target for the treatment of ovarian cancer.
    Shaw D; Clamp A; Jayson GC
    Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of bevacizumab in non-small cell lung cancer: an update.
    Lauro S; Onesti CE; Righini R; Marchetti P
    Anticancer Res; 2014 Apr; 34(4):1537-45. PubMed ID: 24692680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reappraisal of the role of bevacizumab in the therapeutic strategy in advanced renal cell carcinoma.
    Guillot A; Levy A; Pacaut C; Collard O; Massard C; Merrouche Y; Magné N
    Clin Genitourin Cancer; 2012 Sep; 10(3):147-52. PubMed ID: 22796529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current status of anti-angiogenic agents in the treatment of ovarian carcinoma.
    Sánchez-Muñoz A; Pérez-Ruiz E; Mendiola Fernández C; Alba Conejo E; González-Martín A
    Clin Transl Oncol; 2009 Sep; 11(9):589-95. PubMed ID: 19775998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives.
    Colombo N; Conte PF; Pignata S; Raspagliesi F; Scambia G
    Crit Rev Oncol Hematol; 2016 Jan; 97():335-48. PubMed ID: 26555461
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.